ArticleJournal of pharmacy & bioallied sciences2024
Hypermagnesemia with Dystonia Type 2: Case Report of a New SLC30A10 Variant.
Article in Journal of pharmacy & bioallied sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Manganese-induced neurological disorder (HMNDYT1) is a rare condition characterized by the accumulation of manganese in the brain, leading to neurological symptoms such as difficulties in walking. This disorder arises due to genetic mutations affecting manganese transport and metabolism. Presented is the case of a 5-year-9-month-old female from the south region, evaluated for walking difficulties. Born to non-consanguineous parents, her early developmental milestones were typical. However, her initial workup revealed polycythemia and hypermagnesemia, with significantly elevated manganese concentrations in whole blood (880 μg/L). Whole exome sequencing identified a novel missense homozygous variant (c. 137C>A p.(Ser46Tyr)) in the SLC30A10 gene, classified as a variant of uncertain significance (class 3) by the ACMG scheme. Furthermore, both parents were carriers of a heterozygous missense pathogenic variant (c. 1336G>C p.(Asp446His)) in the HMNDYT1 gene. MRI results confirmed manganese deposition in the basal ganglia and other brain regions. Management included biweekly phlebotomies for polycythemia and oral iron supplementation to reduce hypermagnesemia absorption. After two months, the patient was scheduled to be reviewed for CBC, LFT, RFT, MRI, and bone profile analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.